Papadopoulos Nikolaos, Griveas Ioannis, Sveroni Eirini, Argiana Vasiliki, Kalliaropoulos Antonios, Martinez-Gonzalez Beatriz, Deutsch Melanie
1 1st Department of Internal Medicine, 417 Army Share Fund Hospital of Athens, Athens, Greece.
2 Nephrology Department, 417 Army Share Fund Hospital of Athens, Athens, Greece.
Int J Artif Organs. 2018 Mar;41(3):168-170. doi: 10.1177/0391398817752326. Epub 2018 Feb 13.
Hepatitis C virus (HCV) infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. The KDIGO HCV guidelines of 2009 recommend that chronic haemodialysis patients be screened for HCV antibody upon admission to the dialysis clinic and every 6 months thereafter if susceptible to HCV infection. However, previous studies have shown the presence of HCV viraemia in anti-HCV-negative haemodialysis patients as up to 22%.
To evaluate the presence of HCV viraemia, using HCV RNA detection, among anti-HCV-negative haemodialysis patients from a tertiary dialysis unit in Athens.
We enrolled 41 anti-HCV-negative haemodialysis patients diagnosed with third-generation enzyme immunoassay. HCV viraemia was evaluated using a sensitive (cut-off: 12 IU/mL) reverse transcriptase polymerase chain reaction (COBAS AmpliPrep/TaqMan system) for HCV RNA.
None of the 41 anti-HCV-negative haemodialysis patients were shown to be viraemic.
Routine HCV RNA testing appears not to be necessary in anti-HCV-negative haemodialysis patients.
丙型肝炎病毒（HCV）感染在透析患者中仍然很常见，但该群体中HCV的自然史尚未完全明了。2009年KDIGO HCV指南建议，慢性血液透析患者在进入透析诊所时应进行HCV抗体筛查，若易感染HCV，则此后每6个月筛查一次。然而，先前的研究表明，抗HCV阴性的血液透析患者中HCV病毒血症的发生率高达22%。
使用HCV RNA检测评估雅典一家三级透析单位中抗HCV阴性血液透析患者的HCV病毒血症情况。
我们纳入了41例经第三代酶免疫测定诊断为抗HCV阴性的血液透析患者。使用针对HCV RNA的敏感（检测下限：12 IU/mL）逆转录聚合酶链反应（COBAS AmpliPrep/TaqMan系统）评估HCV病毒血症。
41例抗HCV阴性的血液透析患者均未检测出病毒血症。
对于抗HCV阴性的血液透析患者，常规的HCV RNA检测似乎没有必要。
